Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Receivables - Net of $129.2 million for Q4 2025, up 41.68% year-over-year from $91.2 million in Q4 2024, and up 41.68% quarter-over-quarter from $91.2 million in Q4 2024.
Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Receivables - Net for 3 consecutive years, with $129.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net rose 41.68% year-over-year to $129.2 million; the TTM figure through Dec 2025 stood at $129.2 million (up 41.68% YoY), while the FY2025 annual figure was $129.2 million, up 48.63% from the prior year.
- Receivables - Net advanced to $129.2 million in Q4 2025 per TLX's latest filing, from $91.2 million in the prior quarter.
- Across five years, Receivables - Net topped out at $129.2 million in Q4 2025 and bottomed at $42.2 million in Q4 2023.
- Historically, Receivables - Net has averaged $87.5 million across 3 years, with a median of $91.2 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables - Net soared 116.25% — and 2025, when it surged 41.68%.
- Telix Pharmaceuticals' Receivables - Net stood at $42.2 million in 2023, then surged by 116.25% to $91.2 million in 2024, then soared by 41.68% to $129.2 million in 2025.
- Business Quant data shows TLX's Receivables - Net at $129.2 million in Q4 2025, $91.2 million in Q4 2024, and $42.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129.20 Mn |
| Dec 31, 2025 | 129.20 Mn |
| Dec 31, 2024 | 91.19 Mn |
| Dec 31, 2024 | 91.19 Mn |
| Dec 31, 2023 | 42.17 Mn |
| Dec 31, 2023 | 42.17 Mn |